Joseph Lacob
CIK 1215490 · last filed 2026-05-22
Joseph Lacob is a corporate insider who has filed 74 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for ALGN, was dated May 22, 2026. Across all open-market trades the lifetime net is −$95.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $209.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN JOSE, CA 95131
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALGN | Director | 1,180,016 | $176.19 | $207.91M | -$95.85M | 52 | 2026-05-22 |
| NPCE | Director | 142,928 | $13.37 | $1.91M | $0 | 11 | 2026-03-24 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | 117,980 | — | — | $0 | 5 | 2011-06-06 |
| EHTH | Director | 31,786 | $0.47 | $14.8K | $0 | 4 | 2007-11-09 |
Recent Filings
74 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | ALGN | Mixed | +1,745 | $0 | EDGAR |
| 2026-03-24 | NPCE | Grant (A) | +865 | $11.2K | EDGAR |
| 2025-12-23 | NPCE | Grant (A) | +678 | $11.2K | EDGAR |
| 2025-09-22 | NPCE | Grant (A) | +1,131 | $11.2K | EDGAR |
| 2025-06-24 | NPCE | Grant (A) | +11,696 | $101.2K | EDGAR |
| 2025-06-09 | NPCE | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | ALGN | Mixed | +1,148 | $0 | EDGAR |
| 2024-06-11 | NPCE | Grant (A) | — | $0 | EDGAR |
| 2024-05-24 | ALGN | Grant (A) | — | $0 | EDGAR |
| 2024-05-21 | ALGN | Exer (M) | +1,029 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.